Top

Published in:

01-02-2017 | Editorial

When to re-dose regadenoson?

Authors: Gregory S. Thomas, MD, MPH, MASNC, Aaron F. Jolly, MD, Michael Safani, PharmD

Published in: Journal of Nuclear Cardiology | Issue 1/2017

Excerpt

Since FDA approval in 2008, regadenoson, an A2A adenosine receptor agonist, has become the most commonly used pharmacological stress testing agent in the U.S.1 In this issue of the Journal, Townsend et al2 address the important question of how to manage re-dosing of regadenoson if it were to become necessary. This information would be helpful, for example, if the FDA approved 0.4 mg (400 μg) dose of regadenoson were administered intravenously (IV) but the radiotracer became inadvertently unavailable or in the case of an infiltrated IV line resulting in the subcutaneous administration of regadenoson. …

Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol 2012;19:126-41.CrossRefPubMed

Townsend R, Rammelsberg D, Kowalsk D, Simmons N, Kitt TM. Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose placebo-controlled study. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0327-9.PubMed

Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20.CrossRefPubMed

Cerqueira MD. Advances of pharmacologic agents in imaging: New A2a receptor agonists. Curr Cardiol Rep 2006;8:119-22.CrossRefPubMed

Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75.CrossRefPubMed

Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702.CrossRefPubMed

Engelstein ED, Lerman BB, Somers VK, Rea RF. Role of arterial chemoreceptors in mediating the effects of endogenous adenosine on sympathetic nerve activity. Circulation 1994;90:2919-26.CrossRefPubMed

Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12.CrossRefPubMed

Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.CrossRefPubMed

10.

Highlights of prescribing information. Lexiscan (regadenoson) injection for intravenous use. https://www.astellas.us/docs/lexiscan.pdf. Accessed 27 Nov 2015.

11.

Bengalorkar GM, Bhuvana K, Sarala N, Kumar TN. Regadenoson. J Postgrad Med 2012;58:140-6.CrossRefPubMed

12.

Anand-Srivastava MB, Cantin M, Ballak M, Picard S. Desensitization of the stimulatory A2 adenosine receptor-adenylate cyclase system in vascular smooth muscle cells from rat aorta. Mol Cell Endocrinol 1989;62:273-9.CrossRefPubMed

13.

Ramkumar V, Olah ME, Jacobson KA, Stiles GL. Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol 1991;40:639-47.PubMed

14.

Makujina SR, Mustafa SJ. Adenosine-5’-uronamides rapidly desensitize the adenosine A2 receptor in coronary artery. J Cardiovasc Pharmacol 1993;22:506-9.CrossRefPubMed

15.

Trochu JN, Zhao G, Post H, Xu X, Belardinelli L, Belloni FL, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003;41:132-9.CrossRefPubMed

16.

Lette J, Bertrand C, Gossard D, Ruscito O, Cerino M, McNamara D, et al. Long-term risk stratification with dipyridamole imaging. Am Heart J 1995;129:880-6.CrossRefPubMed

17.

Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994;23:384-9.CrossRefPubMed

18.

Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.CrossRefPubMed

19.

Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, Investigators A-MT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.CrossRefPubMed

Title: When to re-dose regadenoson?
Authors: Gregory S. Thomas, MD, MPH, MASNC
Aaron F. Jolly, MD
Michael Safani, PharmD
Publication date: 01-02-2017
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0376-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

When to re-dose regadenoson?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism?

Industry corner: Invitation from JNC to industry scientists

Assessment of late anthracycline-induced cardiotoxicity by 123I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence

A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results

Measurement of absolute myocardial blood flow in humans using dynamic cardiac SPECT and 99mTc-tetrofosmin: Method and validation

Predicting cardiac events using ventricular dyssynchrony in patients who received implantable cardioverter defibrillators: Are more treatment options required?